Brief: Caredx Announces New Koar Data Linking Elevated Allosure® Kidney To Nearly 3-Fold Higher Risk Of Adverse Graft Outcomes In Patients With Borderline Rejection Or Tcmr At Asn Kidney Week 2026
Yesterday 13:02
BRIEF-Caredx Announces New Koar Data Linking Elevated Allosure® Kidney To Nearly 3-Fold Higher Risk Of Adverse Graft Outcomes In Patients With Borderline Rejection Or Tcmr At Asn Kidney Week 2026 Oct 22 (Reuters) - CareDx, Inc. CDNA.O:
CAREDX ANNOUNCES NEW KOAR DATA LINKING ELEVATED ALLOSURE® KIDNEY TO NEARLY 3-FOLD HIGHER RISK OF ADVERSE GRAFT OUTCOMES IN PATIENTS WITH BORDERLINE REJECTION OR TCMR AT ASN KIDNEY WEEK 2026
Source text: ID:nBw4NczCna
Further company coverage: CDNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CareDx
See all newsBrief: Caredx Announces New Koar Data Linking Elevated Allosure® Kidney To Nearly 3-Fold Higher Risk Of Adverse Graft Outcomes In Patients With Borderline Rejection Or Tcmr At Asn Kidney Week 2026
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
CareDx Inc reports results for the quarter ended June 30 - Earnings Summary
CareDx Q2 revenue beats estimates; outlook lifted
Brief: CareDx Q2 Adjusted EPS USD 0.37 Vs. IBES Estimate USD 0.23